IPM Take
Tardive dyskinesia is often treated as a side effect after the real psychiatric work is done. The German data tell a harsher story.
It is not a marginal complication. It is a chronic, visible and disabling movement disorder that drives hospital use, emergency care and healthcare spending. When fewer than one in four patients receive an approved treatment, the issue is no longer only clinical. It is a failure of recognition, treatment access and system accountability.
Executive Summary
A retrospective claims analysis of German health-insurance data found that people with incident tardive dyskinesia had substantially higher healthcare use and costs than matched controls without tardive dyskinesia. Post-index annual all-cause costs were €13,176 for people with incident TD compared with €7,288 for matched controls, an 80.8% difference driven mainly by inpatient care.
The study used the InGef database and analysed patients from 2016 to 2022. Among 389 adults identified with TD, only 21.1% received either of Germany’s two approved therapies, tiapride or tetrabenazine. The authors also noted that newer VMAT2 inhibitors with Phase III evidence in the United States are not approved in the European Union for TD. The claims-based design cannot establish causation and may underestimate or misclassify TD, but the access signal is hard to ignore.
Why it matters
- Patients / advocates: TD can make movement visible in ways that deepen stigma, distress and social withdrawal.
- Clinicians: Earlier recognition and medication review matter, but treatment choices remain limited in Germany.
- Payers and public authorities: The data challenge the false economy of under-treating a condition that drives costly downstream care.
Tardive dyskinesia is what happens when treatment leaves a mark.
For some people, the movements are subtle. For others, they are impossible to hide: facial grimacing, tongue movements, involuntary limb or trunk movements, difficulty speaking or eating, and the social burden of being visibly unwell.
The German claims data show that ignoring TD does not save money. It simply moves the cost somewhere else.
Patients with incident TD had more hospitalisations, more emergency visits, more neurologist appointments and more prescriptions than matched controls. Annual healthcare costs were nearly double after diagnosis. Yet only around one in five people identified with TD received one of the two approved treatments available in Germany.
That is not a niche prescribing issue. It is a policy failure.
The study also suggests under-recognition. The observed prevalence in the database was lower than estimates from other real-world settings, which may reflect the limits of coding but also the fact that TD can be missed, minimised or attributed to psychiatric illness itself.
This is where neuropsychiatry needs a more honest access conversation.
A movement disorder caused or worsened by treatment should not be treated as an unavoidable price of psychiatric stability. Patients deserve regular assessment, shared decision-making, medication review and access to evidence-based care.
Germany is already paying for TD. The question is whether it will pay earlier for better care, or later for the consequences of leaving people untreated.
